Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Management of hyperhomocysteinemia.

Chan E, Fonseca VA.

Metab Syndr Relat Disord. 2003 Jun;1(2):159-70. doi: 10.1089/154041903322294489.

PMID:
18370637
2.

Effect of pharmacological treatments for diabetes on homocysteine.

Asnani S, Chan E, Murthy SN, McNamara DB, Fonseca VA.

Metab Syndr Relat Disord. 2003 Jun;1(2):149-58. doi: 10.1089/154041903322294470.

PMID:
18370636
3.

Lifestyle, homocysteine, and the metabolic syndrome.

Kulkarni K, Richard BC.

Metab Syndr Relat Disord. 2003 Jun;1(2):141-7. doi: 10.1089/154041903322294461. No abstract available.

PMID:
18370635
4.

Methods in assessing homocysteine metabolism.

Murthy SN, Matta AS, Mondal D, McNamara DB.

Metab Syndr Relat Disord. 2003 Jun;1(2):129-40. doi: 10.1089/154041903322294452.

PMID:
18370634
5.

Hormonal regulation of homocysteine.

Randeva HS.

Metab Syndr Relat Disord. 2003 Jun;1(2):121-8. doi: 10.1089/154041903322294443. No abstract available.

PMID:
18370633
6.

Epidemiology of homocysteine as a risk factor in diabetes.

Becker A, Smulders YM, van Guldener C, Stehouwer CD.

Metab Syndr Relat Disord. 2003 Jun;1(2):105-20. doi: 10.1089/154041903322294434.

PMID:
18370632
7.

Hyperhomocysteinemia and cardiovascular disease: new mechanisms beyond atherosclerosis.

Joseph J, Joseph L.

Metab Syndr Relat Disord. 2003 Jun;1(2):97-104. doi: 10.1089/154041903322294425.

PMID:
18370631
8.

Hyperhomocysteinemia and the metabolic syndrome: is there a connection?

Fonseca V.

Metab Syndr Relat Disord. 2003 Jun;1(2):95-6. doi: 10.1089/154041903322294416. No abstract available.

PMID:
18370630
9.

Editorial.

Dandona P.

Metab Syndr Relat Disord. 2003 Jun;1(2):93. doi: 10.1089/154041903322294407. No abstract available.

PMID:
18370629
10.

Methionine metabolism in mammals.

Finkelstein JD.

J Nutr Biochem. 1990 May;1(5):228-37. No abstract available.

PMID:
15539209
11.

Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus.

Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T.

Ann Intern Med. 2004 Jan 20;140(2):94-100.

PMID:
14734331
12.

Homocysteine level and other biochemical parameters in cardiovascular disease patients with diabetes mellitus.

Ajabnoor MA, AL-Ama MN, Banjar Z, Rafee AA, Sheweita SA.

Med Sci Monit. 2003 Dec;9(12):CR523-7.

PMID:
14646975
13.

Update on cobalamin, folate, and homocysteine.

Carmel R, Green R, Rosenblatt DS, Watkins D.

Hematology Am Soc Hematol Educ Program. 2003:62-81. Review.

PMID:
14633777
14.

C-reactive protein, inflammation, and coronary risk.

Ridker PM, Morrow DA.

Cardiol Clin. 2003 Aug;21(3):315-25. Review.

PMID:
14621448
15.

Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia.

Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, Yue TL.

Circulation. 2003 Dec 2;108(22):2805-11. Epub 2003 Nov 10.

16.

Serum and urinary nitric oxide in Type 2 diabetes with or without microalbuminuria: relation to glomerular hyperfiltration.

Apakkan Aksun S, Ozmen B, Ozmen D, Parildar Z, Senol B, Habif S, Mutaf I, Turgan N, Bayindir O.

J Diabetes Complications. 2003 Nov-Dec;17(6):343-8.

PMID:
14583179
18.
19.

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.

Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K.

Diabetes Care. 2003 Sep;26(9):2493-9.

PMID:
12941708
20.

Effect of metabolic control on homocysteine levels in type 2 diabetic patients: a 3-year follow-up.

Passaro A, Calzoni F, Volpato S, Nora ED, Pareschi PL, Zamboni PF, Fellin R, Solini A.

J Intern Med. 2003 Sep;254(3):264-71.

Supplemental Content

Support Center